Colorectal cancer (CRC) remains a significant global health concern, being the third most diagnosed cancer and the second leading cause of cancer-related deaths worldwide. In 2020 alone, CRC accounted for 1.9 million new cases and nearly 935,000 deaths.
Potential epigenetic modifiers targeting the alteration of methylation in colorectal cancer retrieved 23 July 2024 from https://medicalxpress.com/news/2024-07-potential-epigenetic-methylation-colorectal-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.4 hours agoUse this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Potential new target for colorectal cancer treatmentResearchers have identified a protein called PFDN6 that may play a role in the development and spread of colorectal cancer (CRC). The study, published in [journal name], found that PFDN6 levels are increased in CRC patients and contribute to tumor growth.
Read more »
New biomarker shows potential to evaluate treatment response for metastatic colorectal cancerColorectal cancer is the second leading cause of cancer deaths worldwide and the third most diagnosed cancer, affecting over a million people annually. The problem worsens if the tumor is metastatic, meaning it moves from the original organ to other parts of the body. In this scenario, the five-year survival rate drops from 70–90% to just 10%.
Read more »
Fecal immunochemical test screening found to lower risk of death from colorectal cancerScreening with fecal immunochemical tests (FITs) lowers the risk of dying from colorectal cancer (CRC), according to a study published online July 19 in JAMA Network Open.
Read more »
PFDN6 protein could be a new target for colorectal cancer treatmentResearchers have identified a protein called PFDN6 that may play a role in the development and spread of colorectal cancer (CRC).
Read more »
The current state of immunotherapy in colorectal cancerColorectal cancer (CRC) is a major health concern worldwide, characterized by high incidence and mortality rates. Despite advances in treatment, metastatic CRC (mCRC) remains particularly challenging.
Read more »
Mainz Biomed seeks FDA’s Breakthrough Devices Designation for advanced colorectal cancer testMainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has submitted its application to the U.S.
Read more »